These findings indicate that calcitriol effectively suppresses ERK activation, particularly when used in combination with antiestrogens and tyrosine kinase inhibitors, supporting its potential role in modulating MAPK/ERK signaling in HER2-positive breast cancer cells. The gene discussed is ERBB2; the disease is breast carcinoma.